This PDF is the current document as it appeared on Public Inspection on 03/12/2014 at 08:45 am.
By Notice dated September 27, 2013, and published in the Federal Register on October 25, 2013, 78 FR 64018, Nektar Therapeutics, 1112 Church Street, Huntsville, Alabama 35801, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of Fentanyl (9801), a basic Start Printed Page 14299class of controlled substance listed in schedule II.
The company plans to manufacture the listed controlled substance in support of product development.
No comments or objections have been received. The DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Nektar Therapeutics to manufacture the listed basic class of controlled substance is consistent with the public interest at this time. The DEA has investigated Nektar Therapeutics to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history.Start Signature
Dated: Signed February 19, 2014.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.
[FR Doc. 2014-05489 Filed 3-12-14; 8:45 am]
BILLING CODE 4410-09-P